Oruka Therapeutics (ORKA) Expected to Announce Quarterly Earnings on Thursday

Oruka Therapeutics (NASDAQ:ORKA) is projected to post its quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect Oruka Therapeutics to post earnings of ($0.68) per share for the quarter.

Oruka Therapeutics Price Performance

Shares of ORKA opened at $10.86 on Tuesday. Oruka Therapeutics has a 12-month low of $10.57 and a 12-month high of $53.88. The stock has a market capitalization of $380.09 million, a price-to-earnings ratio of -1.73 and a beta of 0.77. The firm has a 50-day moving average price of $15.40.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on ORKA shares. Wedbush reissued an “outperform” rating and issued a $40.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, November 19th. Wolfe Research assumed coverage on Oruka Therapeutics in a research note on Tuesday, February 4th. They set an “outperform” rating and a $20.00 target price for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $45.00 price target on shares of Oruka Therapeutics in a research note on Friday, February 7th. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $39.86.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.